TerminatedPhase 3

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

Chile, United Kingdom89 participantsStarted 2009-10

Plain-language summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Moderate-to-Severe Alzheimer's disease * Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive * Stable on donepezil for at least 6 months Exclusion Criteria: * Other causes of dementia * Major structural brain disease * Unstable medical condition or significant hepatic or renal disease

What they're measuring

Neuropsychiatric Inventory (NPI)

Timeframe: 26 weeks post baseline

Activities of Daily Living (severe) (ADCS ADLsev)

Timeframe: 26 weeks post baseline

Trial details

NCT IDNCT00954590

SponsorMedivation, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-08

View on ClinicalTrials.gov More Moderate to Severe Alzheimer trials